October 13, 2018

CORT: Corcept Therapeutics Incorporated Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	5,876.84
Enterprise Value ($M)	5,739.55
Book Value ($M)	638.84
Book Value / Share	6.10
Price / Book	9.20
NCAV ($M)	321.56
NCAV / Share	3.07
Price / NCAV	18.28

Profitability (mra)
Return on Invested Capital (ROIC)	0.22
Return on Assets (ROA)	0.24
Return on Equity (ROE)	0.31

Liquidity (mrq)
Quick Ratio	3.64
Current Ratio	3.70

Balance Sheet (mrq) ($M)
Current Assets	466.98
Assets	784.26
Liabilities	145.42
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
03-27	13G/A	Ingalls & Snyder Llc	8.00	16.53
02-14	13G/A	Baker G Leonard Jr	5.30	0.50
02-13	13G/A	Vanguard Group Inc	9.25	-7.81
02-13	13G/A	Renaissance Technologies Llc	6.52	-7.72
02-12	13G/A	Belanoff Joseph K	6.10	8.22
01-22	13G/A	BlackRock, Inc.	15.90	0.37

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-10-30	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-07-29	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-05-01	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-02-15	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-21	124,401	493,673	25.20
2024-11-20	166,852	822,512	20.29
2024-11-19	101,117	428,539	23.60
2024-11-18	232,275	656,076	35.40
(click for more detail)

Similar Companies
CNTX – Context Therapeutics Inc.	COCP – Cocrystal Pharma, Inc.
COEP – Coeptis Therapeutics Holdings, Inc.	COYA – Coya Therapeutics, Inc.
CPRX – Catalyst Pharmaceuticals, Inc.

Financial data and stock pages provided by
Fintel.io

Finpedia: Corcept Therapeutics

Related